Table 1.
Comparison of FGF1 to FGF15/19 & FGF21 in diabetic animal models
| General properties1,2 | FGF1 | FGF15/19 | FGF21 |
|---|---|---|---|
| Receptor specificity | All 7 isoforms; Glucose lowering via FGFR1 | Primarily FGFR1 and FGFR4 | Primarily FGFR1 |
| Receptor binding requirements | Heparin dependent | β-klotho co-receptor dependent | β-klotho co-receptor dependent |
| Classification | Autocrine/Paracrine | Autocrine/Endocrine | Autocrine/Endocrine |
| Induction prompt & tissue | Fed state - Adipose | Fed state - Gut | Fasted state - Liver |
| Central actions3,7 | |||
| Feeding suppression | Transient | Transient | None* |
| Glucose lowering (duration) | Months | Hours | Hours |
| Hypoglycemic events | No | NA | NA |
| Insulin sensitizer** | No | No | No |
| Peripheral actions2,8–12 | |||
| Feeding suppression | Transient | None | None*** |
| Glucose lowering (duration) | 3–7 Days | Hours | Hours |
| Hypoglycemic events | None | NA | NA |
| Insulin sensitizer** | Yes | No | No |
Increased food intake
Defined as increased insulin sensitivity not secondary to body weight loss (e.g. TZDs)
Food consumption increased when normalized to dropping body weight
NA, no available data
References
Degirolamo, C., Sabbà, C. & Moschetta, A. Therapeutic potential of the endocrine fibroblast growth factors FGF19, FGF21 and FGF23. Nat Rev Drug Discov 15, 51–69 (2016).
Suh, J. M. et al. Endocrinization of FGF1 produces a neomorphic and potent insulin sensitizer. Nature 513, 436–439 (2014).
Scarlett, J. M. et al. Central injection of fibroblast growth factor 1 induces sustained remission of diabetic hyperglycemia in rodents. Nat. Med. 22, 800–806 (2016).
Ryan, K. K. et al. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 154, 9–15 (2013).
Morton, G. J. et al. FGF19 action in the brain induces insulin-independent glucose lowering. J Clin Invest 123, 4799–4808 (2013).
Marcelin, G. et al. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol Metab 3, 19–28 (2014).
Owen, B. M. et al. FGF21 Acts Centrally to Induce Sympathetic Nerve Activity, Energy Expenditure, and Weight Loss. Cell metabolism 20, 670–677 (2014).
Kir, S. et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 331, 1621–1624 (2011).
Fu, L. et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 145, 2594–2603 (2004).
Xu, J. et al. Acute glucose-lowering and insulin-sensitizing action of FGF21 in insulin-resistant mouse models—association with liver and adipose tissue effects. Am J Physiol Endocrinol Metab 297, E1105–E1114 (2009).
Coskun, T. et al. Fibroblast Growth Factor 21 Corrects Obesity in Mice. Endocrinology 149, 6018–6027 (2008).
Xu, J. et al. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58, 250–259 (2009).